Division Head of Gene Therapy Research & Technical Operations, Astellas
Mathew Pletcher, Ph.D. is Division Head of Gene Therapy Research & Technical Operations for Astellas Gene Therapies. He is responsible for advancing the company’s pipeline from discovery through to IND-enabling preclinical development and for all Manufacturing, Supply Chain, Facilities & Engineering, and Process & Analytical Development functions.
Prior to joining Astellas Gene Therapies (formerly Audentes Therapeutics) in July 2020, Mr. Pletcher worked at Roche Pharma where he was Head of Rare Diseases Research and Early Development, and prior to that, Head of Discovery. Previously, he served as Acting Chief Scientific Officer at Autism Speaks and earlier as Vice President, Head of Genomic Sciences. He also spent eight years working in Pfizer’s Rare Diseases Research Unit in various scientific roles of increasing responsibility including Director, Rare Diseases Research Unit.
Mr. Pletcher also founded and leads a non-profit foundation, Fund for Sight, supporting research and resources for families and children impacted by the genetic disease his daughter inherited called Leber Congenital Amaurosis. He holds a Bachelor of Science in Biology from Duquesne University and a Ph.D. in Human Genetics form Johns Hopkins School of Medicine.